AlveoliX
AlveoliX has developed an adaptable organ-on-chip platform that enables the modelling of all tissue barriers, including the associated mechanical forces. Our technology is suitable for a wide range of applications including drug safety and efficacy testing, inhalation toxicology assessment and answering fundamental research questions. Our technology can be implemented in your laboratory, or utilised through our CRO services
SynVivo, Inc.
Organ-on-Chip models from SynVivo recreate complex microvasculature including scale, morphology, hemodynamic shear stress, and cellular interactions in a perfused microfluidic chip environment. Validated models include Air Liquid Interface for Lung, Blood-Brain Barrier, Tumor, DIVI, Inflammation.
InSphero
InSphero is the pioneer of industrial-grade, 3D-microtissue-based assay solutions and scaffold-free 3D organ-on-a-chip technology. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and immuno oncology.
Hesperos Inc.
Hesperos is accelerating drug discovery by providing safety and efficacy testing services using its Human-on-a-Chip, microphysiological system. This breakthrough technology enables unprecedented preclinical insight bringing better therapies to patients faster without the need for animal testing.
Altis Biosystems
Altis Biosystems has developed a stem cell platform that recreates the human intestinal epithelium, using proliferative stem cells and terminally differentiated cells. These cells are sourced from transplant-grade intestine. It is a high-throughput format, ideal for drug screening.
MIMETAS
Mimetas develops high-throughput healthy and diseased organ-on-a-chip models in the OrganoPlate®, a screening-compatible microfluidics platform that supports the recreation of native tissue structures, and their interaction with compounds, signaling factors, disease triggers, and co-cultured cell types.